|
|
||||||||
Department of Microbiology and Immunology and Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642
Immunotherapy of cancer is attractive because of its potential for specificity and limited side effects. The efficacy of this approach may be improved by providing adjuvant signals and an inflammatory environment for immune cell activation. We evaluated antitumor immune responses in mice after treatment of OVA-expressing B16-F0 tumors with single (15 Gy) or fractionated (5 x 3 Gy) doses of localized ionizing radiation. Irradiated mice had cells with greater capability to present tumor Ags and specific T cells that secreted IFN-
upon peptide stimulation within tumor-draining lymph nodes than nonirradiated mice. Immune activation in tumor-draining lymph nodes correlated with an increase in the number of CD45+ cells infiltrating single dose irradiated tumors compared with nonirradiated mice. Similarly, irradiated mice had increased numbers of tumor-infiltrating lymphocytes that secreted IFN-
and lysed tumor cell targets. Peptide-specific IFN-
responses were directed against both the class I and class II MHC-restricted OVA peptides OVA257264 and OVA323339, respectively, as well as the endogenous class I MHC-restricted B16 tumor peptide tyrosinase-related protein 2180188. Adoptive transfer studies indicated that the increased numbers of tumor Ag-specific immune cells within irradiated tumors were most likely due to enhanced trafficking of these cells to the tumor site. Together these results suggest that localized radiation can increase both the generation of antitumor immune effector cells and their trafficking to the tumor site.
This article has been cited by other articles:
![]() |
A. Jorritsma, A. D. Bins, T. N.M. Schumacher, and J. B.A.G. Haanen Skewing the T-Cell Repertoire by Combined DNA Vaccination, Host Conditioning, and Adoptive Transfer Cancer Res., April 1, 2008; 68(7): 2455 - 2462. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. J. Wong, R. Bos, and L. A. Sherman Tumor-Specific CD4+ T Cells Render the Tumor Environment Permissive for Infiltration by Low-Avidity CD8+ T Cells J. Immunol., March 1, 2008; 180(5): 3122 - 3131. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Lugade, E. W. Sorensen, S. A. Gerber, J. P. Moran, J. G. Frelinger, and E. M. Lord Radiation-Induced IFN-{gamma} Production within the Tumor Microenvironment Influences Antitumor Immunity J. Immunol., March 1, 2008; 180(5): 3132 - 3139. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Stoitzner, L. K. Green, J. Y. Jung, K. M. Price, C. H. Tripp, B. Malissen, A. Kissenpfennig, I. F. Hermans, and F. Ronchese Tumor Immunotherapy by Epicutaneous Immunization Requires Langerhans Cells J. Immunol., February 1, 2008; 180(3): 1991 - 1998. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Galili, K. Wigglesworth, and U. M. Abdel-Motal Intratumoral Injection of {alpha}-gal Glycolipids Induces Xenograft-Like Destruction and Conversion of Lesions into Endogenous Vaccines J. Immunol., April 1, 2007; 178(7): 4676 - 4687. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Beltran, A. K. Ghosh, and S. Basu Immunotherapy of Tumors with Neuroimmune Ligand Capsaicin J. Immunol., March 1, 2007; 178(5): 3260 - 3264. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Zhang, N. A. Bowerman, J. K. Salama, H. Schmidt, M. T. Spiotto, A. Schietinger, P. Yu, Y.-X. Fu, R. R. Weichselbaum, D. A. Rowley, et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells J. Exp. Med., January 22, 2007; 204(1): 49 - 55. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Hargadon, C. C. Brinkman, S. L. Sheasley-O'Neill, L. A. Nichols, T. N. J. Bullock, and V. H. Engelhard Incomplete Differentiation of Antigen-Specific CD8 T Cells in Tumor-Draining Lymph Nodes J. Immunol., November 1, 2006; 177(9): 6081 - 6090. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Reits, J. W. Hodge, C. A. Herberts, T. A. Groothuis, M. Chakraborty, E. K.Wansley, K. Camphausen, R. M. Luiten, A. H. de Ru, J. Neijssen, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy J. Exp. Med., May 15, 2006; 203(5): 1259 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Frey and N. Monu Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response J. Leukoc. Biol., April 1, 2006; 79(4): 652 - 662. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, and L. E. French Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection J. Immunol., January 1, 2006; 176(1): 61 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Casares, M. O. Pequignot, A. Tesniere, F. Ghiringhelli, S. Roux, N. Chaput, E. Schmitt, A. Hamai, S. Hervas-Stubbs, M. Obeid, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death J. Exp. Med., December 19, 2005; 202(12): 1691 - 1701. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |